The cliff was never the crisis: Pharma’s strategy problem

Author(s): Amanjeet Singh Saluja, Axtria

Let me start with something most strategy decks dance around: the patent cliff isn't the problem. It's the symptom.

Every commercial leader knows the headlines. Evaluate estimates that more than $300 billion in branded drug sales will lose patent protection between 2025 and 2030, roughly a sixth of the industry's revenue base. The first round of Medicare-negotiated prices took effect on 1st January, with cuts ranging from 38% to 79% below list prices. Most-Favoured-Nation pricing, tariffs, even the idea of government-led drug purchasing moved from policy debate to operational reality in what felt like the blink of an eye. By 2029, Medicare negotiation will expand to twenty drugs a year.

The natural reaction is to treat 2026 as a revenue problem. Defend price. Cut costs. Protect margins. Wait for conditions to improve.

That instinct may end up costing more than the patent cliff itself.

Because this was never really a pricing issue. It's a strategy issue.